Inhibition of 125I-IL-8- and 125I-NAP–2 Binding to PMN by α-CXCR–1 and α-CXCR–2 Antibodies
| Antibody* . | % Specific Binding‡ . | |
|---|---|---|
| . | 125I-IL–8 . | 125I-NAP–2 . |
| α-CXCR–1 | 65.6 ± 0.6ρ | 99.5 ± 10.6 |
| α-CXCR–2 | 75.0 ± 2.6 | 42.3 ± 5.1 |
| α-CXCR–1 + α-CXCR–2 | 45.5 ± 4.9 | ND |
| α-CXCR–1 + α-CXCR–2 + peptide-1 + peptide-2† | 105.0 ± 7.1 | ND |
| Antibody* . | % Specific Binding‡ . | |
|---|---|---|
| . | 125I-IL–8 . | 125I-NAP–2 . |
| α-CXCR–1 | 65.6 ± 0.6ρ | 99.5 ± 10.6 |
| α-CXCR–2 | 75.0 ± 2.6 | 42.3 ± 5.1 |
| α-CXCR–1 + α-CXCR–2 | 45.5 ± 4.9 | ND |
| α-CXCR–1 + α-CXCR–2 + peptide-1 + peptide-2† | 105.0 ± 7.1 | ND |
Abbreviation: ND, not determined.
PMN were left untreated or preincubated for 60 minutes with α-CXCR–1 antibody SE-2 (100 μg/mL), α-CXCR–2 antibody RII115 (100 μg/mL), or with both antibodies in combination (each at 100 μg/mL).
A 100-fold molar excess of peptide-1 (CXCR-1[1-30]) and peptide-2 (CXCR-2[6-29]) was added.
PMN were incubated with 2 nmol/L 125I-IL–8 or 2 nmol/L 125I-NAP–2. Unspecific binding was determined in the presence of a 100-fold molar excess of the respective unlabeled ligand. Specific binding was calculated by subtraction of unspecific binding from total binding.
ρ Data are expressed as the percentage of specific binding of 125I-IL–8 (4,925 ± 647 cpm) or 125I-NAP–2 (2,082 ± 601 cpm) to untreated cells and represent mean ± SD of three different experiments.